Sign in or create an account to add this stock to your watchlist.
Alere Inc. is a provider of health information through diagnostic tests. The Company's segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its joint venture with The Procter & Gamble Company (P&G). The Company's professional diagnostic solutions allow patients and their healthcare providers to work together to manage patients' conditions over the continuum of care, from the hospital to home. The Company offers lines of drugs-of-abuse tests, reagent systems and laboratory testing options.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryHealth Care Supplies
SectorN/A
SymbolNYSE:ALR
CUSIP01449J10
Phone+1-781-6473900
Debt
Debt-to-Equity Ratio2.43
Current Ratio2.04
Quick Ratio1.54
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-16.86%
Return on Equity-33.39%
Return on Assets-6.72%
Miscellaneous
Employees9,700
Outstanding Shares87,580,000
Alere (NYSE:ALR) Frequently Asked Questions
What is Alere's stock symbol?
Alere trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALR."
How were Alere's earnings last quarter?
Alere Inc (NYSE:ALR) posted its quarterly earnings data on Friday, November, 4th. The medical research company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.54 by $0.35. The medical research company earned $582 million during the quarter, compared to analysts' expectations of $605.50 million. Alere had a negative net margin of 16.86% and a negative return on equity of 33.39%. Alere's revenue for the quarter was down 3.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.10) EPS. View Alere's Earnings History.
What price target have analysts set for ALR?
3 analysts have issued 12 month target prices for Alere's shares. Their predictions range from $51.00 to $51.00. On average, they anticipate Alere's stock price to reach $51.00 in the next year. View Analyst Ratings for Alere.
What are Wall Street analysts saying about Alere stock?
Here are some recent quotes from research analysts about Alere stock:
- 1. According to Zacks Investment Research, "Alere Inc., formerly known as Inverness Medical Innovations, Inc., provides products and services, which focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Alere is headquartered in Waltham, Massachusetts. " (8/17/2017)
- 2. BTIG Research analysts commented, "Continued Growth in Infectious Disease Business Yesterday, Alere filed its preliminary unaudited 10-K and proxy statements following review of matters in South Korea and Japan, and expects to file their Form 10-K by June 15th, 2017. The preliminary financial statements included 4Q16 and FY2016 results, as well as re- statements for revenue recognition during 2014, 2015, and 2016. Topline preliminary 1Q17 financial results were also provided. The filing of the proxy indicates a decoupling process versus the 10-K filing, allowing the shareholder meeting to likely occur between mid-to-late July. The company must resolve outstanding accounting issues and file the 10K by June 15 th or face another negotiation with the creditors and bond holders. We remain Neutral as we continue to think that the deal with Abbott (ABT, Buy, $50PT) will close at the stated terms of $51 per share later this year." (5/24/2017)
Who are Alere's key executives?
Alere's management team includes the folowing people:
- Gregg J. Powers, Independent Chairman of the Board
- Namal Nawana, President, Chief Executive Officer, Director
- James F. Hinrichs, Chief Financial Officer, Executive Vice President
- Daniella Cramp, Global President - Cardiometabolic Business Unit
- Sanjay Malkani, Global President - Toxicology
- Avi Pelossof, Global President - Infectious Disease Business Unit
- Ellen Chiniara J.D., Senior Vice President, General Counsel, Chief Ethics and Compliance Officer, Secretary
- Robert Hargadon, Senior Vice President - Global Human Resources
- John Bridgen Ph.D., Senior Vice President - Business Development
- Mark Gladwell, Senior Vice President - Global Operations
Has Alere been receiving favorable news coverage?
News articles about ALR stock have trended somewhat positive on Thursday, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alere earned a media sentiment score of 0.21 on Accern's scale. They also assigned news coverage about the medical research company an impact score of 47.67 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
What is Alere's stock price today?
One share of ALR stock can currently be purchased for approximately $50.99.
How big of a company is Alere?
Alere has a market capitalization of $4.47 billion. Alere employs 9,700 workers across the globe.
How can I contact Alere?
Alere's mailing address is 51 Sawyer Rd Ste 200, WALTHAM, MA 02453-3448, United States. The medical research company can be reached via phone at +1-781-6473900.
MarketBeat Community Rating for Alere (ALR)
MarketBeat's community ratings are surveys of what our community members think about Alere and other stocks. Vote "Outperform" if you believe ALR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Alere (NYSE:ALR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Alere in the last 12 months. Their average twelve-month price target is $51.00, suggesting that the stock has a possible upside of 0.02%. The high price target for ALR is $51.00 and the low price target for ALR is $51.00. There are currently 3 hold ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.00 | 2.00 | 2.00 | 2.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $51.00 | $51.00 | $51.00 | $51.00 |
| Price Target Upside: | 0.02% upside | 0.99% upside | 0.99% upside | 0.99% upside |
Alere (NYSE:ALR) Consensus Price Target History
Alere (NYSE:ALR) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Alere (NYSE:ALR) Earnings History and Estimates Chart
Alere (NYSE ALR) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/3/2017 | Q2 2017 | | $0.09 | | $557.67 million | View | N/A |  |
| 6/14/2017 | Q1 2017 | $0.39 | $0.42 | $588.22 million | $588.22 million | View | N/A | |
| 6/5/2017 | Q4 2016 | | $0.68 | | $596.81 million | View | N/A | |
| 11/4/2016 | Q3 16 | $0.54 | $0.19 | $605.50 million | $582.00 million | View | N/A | |
| 9/6/2016 | Q216 | $0.58 | ($0.46) | $621.95 million | $611.10 million | View | N/A | |
| 8/17/2016 | Q116 | $0.56 | ($0.18) | | $578.00 million | View | N/A | |
| 8/8/2016 | Q415 | $0.58 | ($0.28) | $662.04 million | $623.00 million | View | N/A | |
| 11/4/2015 | Q315 | $0.55 | $0.49 | $646.29 million | $602.00 million | View | N/A | |
| 8/4/2015 | Q215 | $0.53 | $0.49 | $625.67 million | $629.00 million | View | N/A | |
| 5/5/2015 | Q115 | $0.49 | $0.57 | $612.93 million | $610.40 million | View | N/A | |
| 2/10/2015 | Q414 | $0.63 | $0.61 | $698.56 million | $666.90 million | View | N/A | |
| 10/28/2014 | Q314 | $0.52 | $0.48 | $743.30 million | $736.20 million | View | N/A | |
| 8/4/2014 | Q214 | $0.58 | $0.43 | $747.55 million | $738.30 million | View | N/A | |
| 4/29/2014 | Q114 | $0.55 | $0.55 | $738.70 million | $716.60 million | View | N/A | |
| 2/6/2014 | Q413 | $0.56 | $0.62 | $770.70 million | $772.30 million | View | N/A | |
| 10/29/2013 | Q313 | $0.53 | $0.59 | $737.66 million | $753.90 million | View | N/A | |
| 7/31/2013 | Q2 2013 | $0.48 | $0.64 | $720.24 million | $764.00 million | View | N/A | |
| 5/9/2013 | Q1 2013 | $0.51 | $0.53 | $727.66 million | $739.20 million | View | N/A | |
| 2/15/2013 | Q4 2012 | $0.57 | $0.55 | $714.75 million | $755.80 million | View | N/A | |
| 11/8/2012 | Q312 | $0.53 | $0.43 | $690.76 million | $691.40 million | View | N/A | |
| 8/8/2012 | | $0.53 | ($0.23) | | | View | N/A | |
| 4/30/2012 | | $0.67 | $0.77 | | | View | N/A | |
| 2/27/2012 | Q4 2011 | $0.68 | $0.74 | | | View | N/A | |
| 2/8/2012 | | $0.71 | $0.74 | | | View | N/A | |
| 10/26/2011 | | $0.57 | $0.67 | | | View | N/A | |
| 7/27/2011 | | $0.58 | $0.46 | | | View | N/A | |
| 4/27/2011 | | $0.61 | $0.61 | | | View | N/A | |
| 2/17/2011 | | $0.66 | $0.71 | | | View | N/A | |
| 11/1/2010 | Q3 2010 | $0.59 | $0.54 | | | View | N/A | |
| 7/28/2010 | Q2 2010 | $0.56 | $0.51 | | | View | N/A | |
| 4/28/2010 | Q1 2010 | $0.59 | $0.58 | | | View | N/A | |
| 2/17/2010 | Q4 2009 | $0.64 | $0.67 | | | View | N/A | |
| 10/27/2009 | Q3 2009 | $0.56 | $0.71 | | | View | N/A | |
| 7/28/2009 | Q2 2009 | $0.53 | $0.57 | | | View | N/A | |
| 4/27/2009 | Q1 2009 | $0.53 | $0.56 | | | View | N/A | |
| 2/18/2009 | Q4 2008 | $0.57 | $0.66 | | | View | N/A | |
| 10/29/2008 | Q3 2008 | $0.41 | $0.40 | | | View | N/A | |
| 7/29/2008 | Q2 2008 | $0.41 | $0.37 | | | View | N/A | |
| 4/24/2008 | Q1 2008 | $0.37 | $0.43 | | | View | N/A | |
| 2/20/2008 | Q4 2007 | $0.34 | $0.34 | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Alere (NYSE:ALR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Alere (NYSE ALR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.66%
Institutional Ownership Percentage: 89.33%
Alere (NYSE ALR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/1/2016 | Melissa Guerdan | SVP | Sell | 2,500 | $54.00 | $135,000.00 | | |
| 11/13/2015 | Robert Bernard Hargadon | SVP | Buy | 1,000 | $38.99 | $38,990.00 | 8,843 | |
| 11/12/2015 | James F Hinrichs | CFO | Buy | 10,000 | $39.97 | $399,700.00 | 30,000 | |
| 9/3/2015 | Mark Gladwell | VP | Sell | 2,651 | $52.27 | $138,567.77 | | |
| 9/3/2015 | Melissa Guerdan | SVP | Sell | 5,135 | $52.00 | $267,020.00 | | |
| 9/1/2015 | Melissa Guerdan | SVP | Sell | 5,000 | $50.48 | $252,400.00 | 5,135 | |
| 8/31/2015 | Mark Gladwell | VP | Sell | 27,513 | $52.23 | $1,437,003.99 | 2,651 | |
| 8/14/2015 | Sanjay Malkani | Insider | Sell | 31,460 | $54.60 | $1,717,716.00 | | |
| 6/8/2015 | Sanjay Malkani | Insider | Sell | 24,331 | $50.87 | $1,237,717.97 | | |
| 6/4/2015 | Sanjay Malkani | Insider | Sell | 15,669 | $52.18 | $817,608.42 | | |
| 6/1/2015 | John Bridgen | SVP | Sell | 7,500 | $51.19 | $383,925.00 | | |
| 4/6/2015 | Melissa Guerdan | SVP | Sell | 2,500 | $50.00 | $125,000.00 | | |
| 3/23/2015 | Melissa Guerdan | SVP | Sell | 13,476 | $48.35 | $651,564.60 | | |
| 3/17/2015 | John Bridgen | SVP | Sell | 25,000 | $48.53 | $1,213,250.00 | | |
| 3/16/2015 | Carla Flakne | CAO | Sell | 8,500 | $48.99 | $416,415.00 | | |
| 1/16/2015 | Carla Flakne | CAO | Sell | 10,000 | $42.45 | $424,500.00 | | |
| 12/24/2014 | Don Dudek | Director | Buy | 40,000 | $0.0125 | $500.00 | | |
| 12/11/2014 | John Bridgen | SVP | Sell | 50,000 | $37.07 | $1,853,500.00 | | |
| 8/15/2014 | Dave Teitel | CFO | Sell | 10,000 | $35.07 | $350,700.00 | | |
| 8/15/2013 | Dave Teitel | CFO | Sell | 10,000 | $31.73 | $317,300.00 | 4,506 | |
| 8/5/2013 | Michael Lester Cotton | Insider | Sell | 12,500 | $33.82 | $422,750.00 | | |
| 5/31/2013 | Michael Lester Cotton | Insider | Sell | 8,750 | $25.86 | $226,275.00 | | |
| 3/5/2013 | John Quelch | Director | Sell | 20,220 | $23.49 | $474,967.80 | | |
(Data available from 1/1/2013 forward)
Alere (NYSE ALR) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | U.S. judge declines to rehear Alere blood monitor class certification bid
www.reuters.com - April 26 at 8:55 AM |
 | Abbott Laboratories Q3 2017 Earnings Conference Call Transcript (ABT)
finance.yahoo.com - April 17 at 5:12 PM |
 | UPDATE 1-Abbott's Alere resolves U.S. diagnostic device probe for $33.2 mln
www.cnbc.com - March 23 at 4:51 PM |
| Abbott's Alere resolves US diagnostic device probe for $33.2 million
www.cnbc.com - March 23 at 1:59 PM |
 | Abbott Labs Has 'An Emerging Picture Of Top-Tier Growth,' Says Morgan Stanley - Benzinga
www.benzinga.com - January 2 at 3:21 PM |
 | Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q3 2017 Update - Seeking Alpha
seekingalpha.com - November 17 at 10:48 AM |
 | Contrasting Alere (ALR) & Cogentix Medical (CGNT)
www.americanbankingnews.com - November 8 at 9:32 PM |
| Alere Inc (ALR) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 6 at 3:46 AM |
| Public health care company to layoff 182, close two South Florida offices
finance.yahoo.com - November 2 at 4:12 PM |
| Alere (ALR) and Its Rivals Head-To-Head Analysis
www.americanbankingnews.com - October 29 at 3:08 AM |
| Alere (ALR) vs. Its Competitors Head to Head Survey
www.americanbankingnews.com - October 15 at 4:28 AM |
| Alere Inc. (ALR) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 12 at 4:46 AM |
| Contrasting Hansen Medical (HNSN) & Alere (ALR)
www.americanbankingnews.com - October 7 at 6:30 PM |
| Alere (ALR) & Its Peers Head-To-Head Comparison
www.americanbankingnews.com - October 7 at 4:18 AM |
| Alere Inc. -- Moody's to withdraw Alere's ratings following debt redemption
finance.yahoo.com - October 5 at 6:13 PM |
 | Alere Announces FDA Clearance For I Influenza A & B 2 Rapid Molecular Test
www.nasdaq.com - October 2 at 3:36 PM |
 | Alere (ALR) Announces FDA Clearance for Alere i Influenza A & B 2 Rapid Molecular Test
www.streetinsider.com - October 2 at 3:36 PM |
| Alere Receives FDA Clearance for Alere™ i Influenza A & B 2 Rapid Molecular Test
finance.yahoo.com - October 2 at 3:36 PM |
| Corporate News Blog - Alere Announces Agreement with the US Department of Justice; Settles the Investigations Concerning Previous Foreign Acquisitions
finance.yahoo.com - October 2 at 3:36 PM |
| FDA clears Alere's second-generation flu test
seekingalpha.com - October 2 at 11:25 AM |
| Alere (ALR) Announces FDA Clearance for Alere i Influenza A & B 2 Rapid Molecular Test - StreetInsider.com
www.streetinsider.com - October 2 at 7:31 AM |
| Alere Reaches Settlement With SEC
finance.yahoo.com - September 30 at 2:13 PM |
| Alere (ALR) Reports U.S. DOJ has Ended Investigation Into Sales, Sales Practices and Dealings with Certain 3rd Parties
www.streetinsider.com - September 30 at 2:13 PM |
| Abbott (ABT) Se to Close Alere (ALR) Takeover on October 3 - StreetInsider.com
www.streetinsider.com - September 29 at 8:20 PM |
 | Alere Announces Agreement In Principle To Settle With U.S. DoJ
www.rttnews.com - September 29 at 3:19 PM |
| Alere Announces the U.S. Department of Justice Closes Investigation
finance.yahoo.com - September 29 at 3:19 PM |
| Alere Reaches Analyst Target Price
www.nasdaq.com - September 29 at 3:19 PM |
| Alere Agrees To Pay More Than $13 Mln To Settle SEC Accounting Fraud Charges
www.nasdaq.com - September 28 at 9:20 PM |
| Abbott wins U.S. antitrust approval to buy Alere with conditions
www.reuters.com - September 28 at 4:17 PM |
| Alere to divest two product lines to get FTC signoff on Abbott merger; shares up 4%
seekingalpha.com - September 28 at 3:23 PM |
| Alere to pay $13M to settle SEC inquiry into revenue recognition issues
seekingalpha.com - September 28 at 12:24 PM |
| Alere, Inc. – Value Analysis (NYSE:ALR) : September 21, 2017
finance.yahoo.com - September 22 at 2:43 PM |
| Alere Inc. (ALR) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - September 20 at 2:38 PM |
| Quidel Corp (QDEL) Gains After Revised Deal on Alere's (ALR) BNP ... - StreetInsider.com
www.streetinsider.com - September 19 at 3:46 PM |
 | Alere Inc. Declares Cash Dividend on its Series B Convertible ... - PR Newswire (press release)
www.prnewswire.com - September 19 at 3:46 PM |
| Alere, Inc. breached its 50 day moving average in a Bullish Manner : ALR-US : September 19, 2017
finance.yahoo.com - September 19 at 3:46 PM |
| Here's Why Quidel Corporation Stock Is Popping Today
finance.yahoo.com - September 19 at 3:46 PM |
| Alere Announces Intent to Voluntarily Delist Series B Convertible Perpetual Preferred Stock from the NYSE Conditioned Upon the Completion of its Acquisition by Abbott
finance.yahoo.com - September 18 at 9:11 PM |
| Mid-Day ETF Update: ETFs, Stocks Higher as Major Indices Reach Fresh All-Time Highs
www.nasdaq.com - September 18 at 4:10 PM |
 | Medical Research Stock Performance Review -- Agilent Technologies, Alere, Quintiles IMS, and Thermo Fisher Scientific
www.bizjournals.com - September 18 at 4:10 PM |
| Alere Inc. (ALR) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 17 at 4:40 AM |
 | ALERE INVESTIGATION INITIATED by Former Louisiana Attorney ... - Business Wire (press release)
www.businesswire.com - September 16 at 3:33 PM |
| Head to Head Comparison: Fulgent Genetic (FLGT) vs. Alere (ALR)
www.americanbankingnews.com - September 11 at 1:08 PM |
| ALERE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick ...
www.prnewswire.com - September 9 at 2:12 AM |
| Alere, Inc. breached its 50 day moving average in a Bearish Manner : ALR-US : September 8, 2017
finance.yahoo.com - September 8 at 4:06 PM |
| Alere (ALR) versus Boston Scientific Corporation (BSX) Head-To-Head Survey
www.americanbankingnews.com - September 6 at 12:22 PM |
| ALERE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the ... - Business Wire (press release)
www.businesswire.com - September 2 at 2:25 AM |
| ALERE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alere Inc. - ALR
finance.yahoo.com - September 2 at 2:25 AM |
| Alere Inc. (ALR) Sees Large Growth in Short Interest
www.americanbankingnews.com - August 31 at 1:46 AM |
| New Strong Sell Stocks for August 28th
finance.yahoo.com - August 28 at 3:51 PM |
Alere (NYSE:ALR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Alere (NYSE:ALR) Income Statement, Balance Sheet and Cash Flow Statement
Alere (NYSE ALR) Stock Chart for Thursday, May, 24, 2018
Loading chart…
